spacer
home > ebr > spring 2002 > harnessing the immune system against cancer
PUBLICATIONS
European Biopharmaceutical Review

Harnessing the Immune System Against Cancer

Cancerous cells contain numerous mutations, qualitative and quantitative, spatial and temporal, relative to their normal, non-cancerous counterparts. At certain periods during tumour cells' growth and spread, a proportion of these are capable of being recognised by the hosts' immune system as abnormal. This has led to numerous research efforts worldwide to develop immunotherapies that harness the power of the hosts' immune system and direct it to attack the cancerous cells, thereby eliminating such aberrant cells at least to a level that is not life-threatening (1,2). The market has recognised the potential of this approach, and the cancer vaccine revenues alone are forecast at US$3 billion by 2008 (3). Numerous approaches have been taken in the quest for cancer immunotherapies, which can be classified under the five categories covered in this article:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Anthony Walker, CEO of Onyvax Ltd

Prior to co-founding Onyvax in 1997, Anthony Walker spent 10 years as a Management Consultant, specialising in the pharmaceutical and biotechnology industries. During his eight years at Arthur D. Little, Anthony was appointed a European Director, responsible for the London-based pharmaceutical practice that he founded, and at The Wilkerson Group (London) he had responsibility for the UK, Benelux and Scandinavian markets.
Anthony has consulted to 12 of the top 25 Rx companies and has also worked closely with over 20 biotechnology companies. In addition, he has produced expert reports for a number of UK biotech IPOs.

spacer
Dr Anthony Walker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

By Your Side for a Healthier World

West Pharmaceutical Services, Inc.

Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement